Clinical Trials Browser

Advanced Solid Tumor

Advanced Solid Tumors

Advanced Solid Tumor

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Advanced Solid Tumour

Colorectal Neoplasms, Neoplasm, Residual

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

Advanced Solid Tumour

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Rectal Neoplasms

Small Cell Lung Carcinoma

MSI-H/dMMR Solid Tumors

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Advanced Non-small Cell Lung Cancer

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Pathologic Complete Response, Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Lymphoma, Follicular

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of External Auditory Canal

Stomach Neoplasms

Carcinoma, Hepatocellular

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Hodgkin Disease, Lymphoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Advanced Solid Tumor

Clinical Trials

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

A Study of SKB518 in Patients With Lung Cancer

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

TNTIT

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

FUTURE

HARBOR

NeoTISLEGA

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

FIL_Tisle-HL

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.